Cargando…
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
The ATAC trial evaluates in a randomized, double-blind design, Arimidex™ (anastrozole) alone or in combination with tamoxifen, relative to tamoxifen alone as 5-year adjuvant treatment in postmenopausal women with early breast cancer. Patients included in the pharmacokinetic (PK) sub-protocol had bee...
Autor principal: | Trialists' Group, The ATAC |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364083/ https://www.ncbi.nlm.nih.gov/pubmed/11487258 http://dx.doi.org/10.1054/bjoc.2001.1925 |
Ejemplares similares
-
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial
por: Mansel, R, et al.
Publicado: (2007) -
Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?
por: Buzdar, A U
Publicado: (2001) -
Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
por: Xanthopoulos, J. M., et al.
Publicado: (2005) -
Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008) -
Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)